Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective cohort in China
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.2979
Abstract: Treatment for relapsed/refractory Diffuse Large B‐Cell Lymphoma (R/R DLBCL) is evolving rapidly due to the emergence of novel drugs, of which histone deacetylase inhibitors (HDACis) are an important example. This study showed efficacy in patients… read more here.
Keywords: single center; cell lymphoma; refractory diffuse; relapsed refractory ... See more keywords
Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2021.1884677
Abstract: ABSTRACT Introduction Patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) require further treatment options, especially in cases that cannot tolerate stem cell transplant or cytotoxic chemotherapy. CD19 has emerged as an attractive… read more here.
Keywords: relapsed refractory; treatment; tafasitamab; diffuse large ... See more keywords
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients.
Sign Up to like & getrecommendations! Published in 2022 at "British journal of haematology"
DOI: 10.1111/bjh.18197
Abstract: Several recently published trials investigate novel therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). To estimate the benefit of these therapies in the real-world setting, comprehensive data on patients treated in clinical routine are… read more here.
Keywords: second line; cell; relapsed refractory; refractory diffuse ... See more keywords
Pixantrone in patients with relapsed/refractory diffuse large B‐cell lymphoma: A real‐life, retrospective, multicenter trial on behalf of the “RTL” (Regional Tuscan Lymphoma network)
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13745
Abstract: Pixantrone is a novel aza‐anthracenedione with antineoplastic activity, currently approved for multiply relapsed/refractory diffuse large B‐cell lymphoma (DLBCL), even if real‐life data are limited. read more here.
Keywords: lymphoma; cell lymphoma; refractory diffuse; relapsed refractory ... See more keywords
Patients’ decision-making, experiences and preferences regarding pixantrone treatment in relapsed or refractory diffuse large B-cell lymphoma: study protocol for a longitudinal mixed methods study
Sign Up to like & getrecommendations! Published in 2019 at "BMJ Open"
DOI: 10.1136/bmjopen-2018-026505
Abstract: Introduction There is a lot of speculation about why and how patients decide to use invasive treatment in an advanced stage of cancer, but the body of research is limited. The present longitudinal qualitative and… read more here.
Keywords: relapsed refractory; study patients; treatment; study ... See more keywords
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Hematology"
DOI: 10.1177/20406207221087511
Abstract: Loncastuximab tesirine-lpyl (ADC Therapeutics) is an anti-CD19 antibody-drug conjugate which consists of anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Data from preclinical in vitro and animal studies demonstrated its selectivity and efficacy. The phase I… read more here.
Keywords: cell; refractory; refractory diffuse; relapsed refractory ... See more keywords
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006415
Abstract: Key Points The level of baseline ctDNA correlated with PFS and OS in patients with R/R DLBCL receiving pola plus BR or BR alone. Patients with a CR had a significantly greater median decrease in… read more here.
Keywords: refractory diffuse; relapsed refractory; diffuse large; profiling patients ... See more keywords
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022009260
Abstract: As part of a phase 1/2 study, this single-arm expansion cohort established the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received >=2 prior lines of therapy).… read more here.
Keywords: mosunetuzumab monotherapy; lymphoma; refractory diffuse; relapsed refractory ... See more keywords